Breast cancer update and MHT Want to know more? See special issue in Maturitas edited by Antonio Cano https://www.sciencedirect.com/journal/maturitas/special-issue/10WWC52H6QN and editorial by Irene Lambrinoudaki and Eleni Armeni https://www.maturitas.org/article/S0378-5122(19)30805-9/abstract
DetailsThe first Global Position Statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), was published in four leading international medical journals on 2 September 2019: Climacteric, Maturitas, The Journal of Sexual Medicine, and The Journal of Clinical Endocrinology and Metabolism. The statement has been authored by a diverse team of leading experts…
Details30 August 2019 A meta-analysis covering the period January 1992 to January 2018 has been published in the Lancet by the Collaborative Group on Hormonal Factors in Breast Cancer. It has reported on the risk of breast cancer with MHT in relation to the type and timing of therapy. During prospective follow-up, 108 647 postmenopausal women…
DetailsAmsterdam, 29 March, 2019 – A new position statement by the European Menopause and Andropause Society (EMAS) published in the journal Maturitas summarises the evidence about predictors of premature or early natural menopause. Almost 1 in 10 women have a menopause that is premature or early. Menopause before the age of 40 isconsidered to be…
Details